Suppressive effects of zingerone on TGFBIp-mediated septic responses

Arch Pharm Res. 2018 Mar;41(3):276-287. doi: 10.1007/s12272-017-0919-9. Epub 2017 May 16.

Abstract

Zingerone (ZGR), a phenolic alkanone isolated from ginger, has been reported to possess various pharmacological activities. Transforming growth factor β-induced protein (TGFBIp) is an extracellular matrix protein whose expression in several cell types is greatly increased by TGF-β. TGFBIp is released by human umbilical vein endothelial cells and functions as a mediator of experimental sepsis. We hypothesized that ZGR could reduce TGFBIp-mediated severe inflammatory responses in human endothelial cells and mice. Here, we investigated the anti-septic effects and underlying mechanisms of ZGR against TGFBIp-mediated septic responses. ZGR effectively inhibited lipopolysaccharide-induced release of TGFBIp and suppressed TGFBIp-mediated septic responses. In addition, ZGR suppressed TGFBIp-induced sepsis lethality and pulmonary injury. In conclusion, ZGR suppressed TGFBIp-mediated and CLP-induced septic responses. Therefore, ZGR could be a potential therapeutic agent for treatment of various severe vascular inflammatory diseases via inhibition of the TGFBIp signaling pathway.

Keywords: HUVEC; Sepsis; Severe inflammation; TGFBIp; Zingerone.

MeSH terms

  • Animals
  • Cell Movement / drug effects
  • Cell Movement / physiology
  • Cell Survival / drug effects
  • Cell Survival / physiology
  • Dose-Response Relationship, Drug
  • Guaiacol / analogs & derivatives*
  • Guaiacol / pharmacology
  • Guaiacol / therapeutic use
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Sepsis / drug therapy*
  • Sepsis / metabolism*
  • Transforming Growth Factor beta / antagonists & inhibitors*
  • Transforming Growth Factor beta / biosynthesis*
  • Treatment Outcome

Substances

  • Transforming Growth Factor beta
  • zingerone
  • Guaiacol